ASTATINE-211 LABELED ANTIBODIES FOR THERAPY

Information

  • Research Project
  • 3614581
  • ApplicationId
    3614581
  • Core Project Number
    N43CM067941
  • Full Project Number
    N43CM067941-000
  • Serial Number
    67941
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/24/1986 - 38 years ago
  • Project End Date
    -
  • Program Officer Name
  • Budget Start Date
    9/24/1986 - 38 years ago
  • Budget End Date
    3/31/1987 - 37 years ago
  • Fiscal Year
    1986
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

ASTATINE-211 LABELED ANTIBODIES FOR THERAPY

The purpose of this contract proposal is to label monoclonal antibodies with astatine-211 for use in radioimmunotherapy. The goal of the proposed research is to develop a method to incorporate astatine into antibodies such that the astatine is not labile in vitro or in vivo. In the investigation, two different approaches to labeling will be compared. One approach will be direct labeling with astatine and the other approach will involve the use of astatinated small molecules. The later approach will include development of methods to attach the astatine to the small molecules such that the astatine is stably attached to them.

IC Name
DIVISION OF CANCER TREATMENT
  • Activity
    N43
  • Administering IC
    CM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
  • Study Section Name
  • Organization Name
    NEORX CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98119
  • Organization District
    UNITED STATES